Affichage 1 à 10 des 22 essais cliniques
ESSAI CLINIQUE No essai ClinicalTrials.gov ID |
Investigateur(trice) principal(e)
Coordonnateur(rice) |
||
---|---|---|---|
(EN) A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies
MK-1026-003 NCT04728893 ![]() |
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
![]() |
Leucémie lymphoïde chronique (LLC) Lymphome non-hodgkinien (LNH) |
Dre Isabelle Fleury Nawel Mechtouf 514-252-3400 poste 4681 |
(EN) A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies
MK-2140-006 NCT05458297 ![]() |
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
![]() |
Leucémie lymphoïde chronique (LLC) Lymphome non-hodgkinien (LNH) |
Dre Sarit Assouline Edrian Gabrielle Bumanlag 514-840-8222 poste 23638 |
(EN) Un registre de données cliniques et paracliniques, incluant une banque de tissus biologiques, de patients atteints d’un lymphome (Registre des lymphomes)
HMR-LYM001 ![]() |
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
![]() |
Lymphome non-hodgkinien (LNH) |
Dre Isabelle Fleury Michel-Olivier Gratton 514-252-3400 poste 2397 |
(EN) A Phase 2, Open-label, Single Arm, Multicenter Trial to Evaluate the Safety and Efficacy of JCAR017 (Lisocabtagene Maraleucel) in Adult Subjects With High-risk, Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
TRANSCEND FL NCT04245839 ![]() |
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
![]() |
Lymphome non-hodgkinien (LNH) |
Dre Isabelle Fleury Olivier Cormier 514-252-3400 poste 5966 |
(EN) A Randomized Phase 3 Trial of Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
COG-ANHL1931 NCT04759586 ![]() |
CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE
|
Lymphome non-hodgkinien (LNH) |
Dre Josette Champagne |
(EN) A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma
OLYMPIA-1 NCT06091254 ![]() |
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
![]() |
Lymphome non-hodgkinien (LNH) |
Dre Stéphanie Corriveau-Désilets Mégane Lebel 819-346-1110 poste 14138 |
(EN) A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma
EPCORE FL-1 NCT05409066 ![]() |
CHU DE QUEBEC – UNIVERSITE LAVAL
![]() |
Lymphome non-hodgkinien (LNH) |
Dr Jean-François Larouche Philippe Nadeau 418-649-0252 poste 63115 |
(EN) A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma
OLYMPIA-1 NCT06091254 ![]() |
CHU DE QUEBEC – UNIVERSITE LAVAL
![]() |
Lymphome non-hodgkinien (LNH) |
Dr Christopher Lemieux Philippe Nadeau 418-649-0252 poste 63115 |
(EN) A Randomized Phase 3 Trial of Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
COG-ANHL1931 NCT04759586 ![]() |
CHU DE QUEBEC – UNIVERSITE LAVAL
![]() |
Lymphome non-hodgkinien (LNH) |
Dr Bruno Michon |
(EN) A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
MOR208C310 (frontMIND) NCT04824092 ![]() |
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
![]() |
Lymphome non-hodgkinien (LNH) |
Dre Nathalie Johnson Ding Yuan Guo 514-340-8222 poste 24599 |